Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| KD | Kyndryl | $10.32 | -$13.17 | -56.07% | 631.1K | $5.4B | $10.11$44.20 |
| PLYX | Polaryx Therapeutics | $6.01 | -$2.90 | -32.55% | 69K | $422M | $2.51$48.91 |
| PFSA | Profusa | $3.31 | -$1.06 | -24.30% | 163.3K | $378M | $3.21$957.00 |
| SMX | Smx (Security Matters) Public | $12.00 | -$3.83 | -24.20% | 2.5M | $138M | $3.12$9,134.28 |
| HIMS | Hims & Hers Health | $17.62 | -$5.40 | -23.46% | 2.2M | $5.2B | $16.36$72.98 |
| RDIB | Reading International | $10.46 | -$3.00 | -22.29% | 22.9K | $306M | $5.81$17.40 |
| MNDY | Monday.com | $77.04 | -$20.96 | -21.39% | 257.3K | $5.0B | $73.01$342.64 |
| PGY | Pagaya Technologies | $14.91 | -$3.73 | -20.01% | 543.1K | $1.5B | $8.50$44.99 |
| CLF | Cleveland-Cliffs | $11.93 | -$2.81 | -19.04% | 27M | $8.4B | $5.63$16.70 |
| SXTC | China Sxt Pharmaceuticals | $2.44 | -$0.56 | -18.67% | 4.1M | $2.6M | $2.41$1,176.00 |
| MPAA | Motorcar Parts Of America | $10.78 | -$2.36 | -17.96% | 4.5K | $257M | $6.04$18.12 |
| FLYE | Fly-E Group | $2.92 | -$0.54 | -15.47% | 115K | $5.6M | $2.73$161.80 |
| ALX | Alexander's | $220.15 | -$34.92 | -13.69% | 2.4K | $1.3B | $189.05$260.84 |
| VHUB | VenHub Global | $4.20 | -$0.63 | -13.04% | 162.2K | $362M | $4.02$40.30 |
| ASST | Strive Asset Management, Llc | $10.48 | -$1.44 | -12.04% | 1.7M | $397M | $7.73$268.40 |
| AXG | Solowin | $3.17 | -$0.43 | -11.94% | 3.3K | $678M | $1.16$5.09 |
| CTEV | Claritev | $22.87 | -$3.04 | -11.73% | 3.5K | $428M | $12.86$74.07 |
| WAT | Waters | $337.57 | -$43.72 | -11.47% | 43.5K | $23B | $275.05$414.15 |
| WSHP | WeShop | $40.24 | -$4.33 | -9.71% | 9.5K | $1.0B | $20.02$250.00 |
| ATLN | Atlantic International | $3.21 | -$0.24 | -6.96% | 23.7K | $216M | $1.16$6.50 |
Related Articles
Featured Article
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Monday.com Stock Is Crashing. Time to Buy the Dip?
Timothy Green|Nov 10, 2025
The software company's slight guidance cut tanked the stock.
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Geoffrey Seiler|Nov 9, 2025
The company continues to have a strong growth outlook ahead.
Hims & Hers Stock Jumps 9% After Huge Announcement
Travis Hoium|Oct 16, 2025
New products are coming to the Hers platform.
1 Growth Stock Down 30% You Don't Want to Miss On
Neil Rozenbaum|Oct 6, 2025
The recent pullback is a blessing in disguise.
Cleveland-Cliffs Stock Just Keeps Dropping. Buying Opportunity, or a Sign to Steer Clear?
Reuben Gregg Brewer|Oct 1, 2025
Cleveland-Cliffs is losing money as the steel industry deals with a downturn, which is exactly why you might want to buy it.
A Healthcare Debate: Progyny vs. Hims & Hers
Motley Fool Staff|Sep 26, 2025
Motley Fool analysts take a look.
